Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure, and prediction of adverse events in a 90-day follow-up period: A prospective clinical observation trial
Open Access
- 8 February 2017
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 13 (4) , 1554-1560
Abstract
The present study compared the prognostic value of a marker, the C-terminal section of the arginine vasopressin prohormone (copeptin), with N-terminal B-type natriuretic peptide (NT-proBNP) in patients with severe acute decompensated heart failure. A prospective, observational cohort study was conducted in a tertiary care hospital and enrolled 129 patients with severe acute decompensated heart failure. Clinicians were blinded to investigational markers except NT-proBNP, and the study participants were followed up for 90 days. The end-point was a composite of cardiovascular death or re-hospitalization due to decompensated heart failure. Of the 129 patients enrolled, 47 reached the end-point and 82 were in a stable condition during follow-up. Receiver operating characteristic curve analysis revealed that the areas under curve for the prediction of adverse events within 90 days were similar for copeptin [0.602±0.052; 95% confidence interval (CI), 0.499–0.705], NT-proBNP (0.659±0.048; 95% CI, 0.565–0.753) and their combination (0.670±0.050; 95% CI, 0.573–0.767). Kaplan-Meier survival analysis showed that the predictive value of NT-proBNP regarding the probability of survival was superior compared with that of copeptin (log-rank test for trend, P=0.001 vs. 0.040). Furthermore, multivariate Cox proportional-hazards regression analysis revealed that increased NT-proBNP and copeptin plasma concentrations were significant independent predictors of adverse events. The present study provided evidence that copeptin has similar predictive properties compared with NT-proBNP regarding adverse events within 90-days in patients with severe acute decompensated heart failure, but that copeptin may not provide superior 90-day prediction compared to NT-proBNP.Keywords
This publication has 25 references indexed in Scilit:
- Neuroimmune Activation in Chronic Heart FailureEndocrine, Metabolic & Immune Disorders - Drug Targets, 2013
- State of the Art: Using Natriuretic Peptide Levels in Clinical PracticeEuropean Journal of Heart Failure, 2008
- Biomarkers in Heart FailureNew England Journal of Medicine, 2008
- COPEPTIN, A STABLE PEPTIDE OF THE ARGININE VASOPRESSIN PRECURSOR, IS ELEVATED IN HEMORRHAGIC AND SEPTIC SHOCKShock, 2007
- N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart FailureCirculation, 2007
- NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patientsEuropean Heart Journal, 2005
- Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart FailureCirculation, 1997
- The epidemiology of heart failureEuropean Heart Journal, 1997
- Products of vasopressin gene expression in small-cell carcinoma of the lungBritish Journal of Cancer, 1994
- Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin–neurophysin II precursorNature, 1982